Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
| Autor: | Stephen J. Kolb, Jerry Reynolds, Songzhu Zhao, Steven Severyn, Kiran F Rajneesh, David Kline, Kristina Kelly, Matthew Linsenmayer, Tristan Weaver, W. David Arnold, Arthur H.M. Burghes, Bakri Elsheikh, Gary Sterling, Sarah Heintzman, Marco Tellez, Amy Bartlett |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
business.industry
Neurosciences. Biological psychiatry. Neuropsychiatry Spinal muscular atrophy Isometric exercise Motor neuron medicine.disease SMA Neuromuscular junction Compound muscle action potential EMG medicine.anatomical_structure Neurology Anesthesia medicine Nusinersen neuromuscular Neurology (clinical) Repetitive nerve stimulation business Original Research spinal muscular atrophy RC321-571 |
| Zdroj: | BMJ Neurology Open, Vol 3, Iss 2 (2021) BMJ Neurology Open |
| ISSN: | 2632-6140 |
| Popis: | ObjectiveSpinal muscular atrophy (SMA) is a motor neuron disease caused by low levels of survival motor neuron (SMN) protein. Prior work in models and patients has demonstrated electrophysiological and morphological defects at the neuromuscular junction (NMJ). Therapeutic development has resulted in clinically available therapies to increase SMN protein levels in patients and improve muscle function. Here we aimed to investigate the effect of SMN restoration (via nusinersen) on NMJ transmission in adults with SMA.MethodsParticipants undergoing nusinersen treatment underwent 3 Hz repetitive nerve stimulation (RNS) of the spinal accessory nerve to assess compound muscle action potential amplitude decrement. Maximum voluntary isometric contraction (MVICT), Revised Upper Limb Module (RULM), and 6 min walk test (6MWT) were assessed for correlations with decrement.ResultsData from 13 ambulatory (7 men/6 women, mean age 40±11 years) and 11 non-ambulatory (3 men/8 women, mean age 38±12 years) participants were analysed. Cross-sectional analyses of RNS decrement were similar at 14 months of nusinersen (−14.2%±11.5%, n=17) vs baseline (−11.9%±8.3%, n=15) (unpaired t-test, p=0.5202). Longitudinal comparison of decrement in eight participants showed no change at 14 months (−13.9%±6.7%) vs baseline (−16.9%±13.4%) (paired t-test, p=0.5863). Decrement showed strong correlations with measures of MVICT, RULM and 6MWT but not age or disease duration.ConclusionAdults with SMA had significant NMJ transmission defects that were not corrected with 14 months of nusinersen treatment. NMJ defects were negatively associated with physical function, and thus may represent a promising target for additive or combinatorial treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|